U.S. FDA approves Biogen Alzheimer's drug, shares soar

by redpill Mon Jun 07, 2021 4:24 pm

Mon Jun 07, 2021 4:22 pm

U.S. FDA approves Biogen Alzheimer's drug, shares soar

https://www.yahoo.com/news/u-fda-set-rule-controversial-100631773.html

Biogen said it has priced the drug, to be sold as Aduhelm, at $56,000 per year. Its shares jumped nearly 52% to $434.52 when trading resumed following the approval. U.S. traded shares of partner Eisai Co were already up $33.50, or 45%, to $107.75

$56,000 per year Suspect